Gilead Sciences Inc.
Gilead Sciences Announces Issuance of Senior Notes
Summary
On May 20, 2026, Gilead Sciences, Inc. announced the issuance of $500,000,000 aggregate principal amount of 4.250% Senior Notes due 2028, $1,000,000,000 aggregate principal amount of 4.400% Senior Notes due 2029, $1,000,000,000 aggregate principal amount of 4.600% Senior Notes due 2031, and $500,000,000 aggregate principal amount of 4.900% Senior Notes due 2034. The net proceeds from the sale of the Notes will be used for general corporate purposes, including funding for acquisitions, investments, strategic transactions, or other business opportunities. The issuance is subject to certain restrictions, including limitations on creating or incurring secured indebtedness and entering into sale and leaseback transactions. The company may redeem some or all of the Notes at any time and from time to time at the applicable redemption prices.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement